Innovating Works

TLS-S

Desconocido
Inno4Vac: Innovations to accelerate vaccine development and manufacture Toscana Life Sciences Sviluppo participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado
TRANSVAC-DS: DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE Toscana Life Sciences Sviluppo participó en un H2020: H2020-SC5-2018-2019-2020 The TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishme...
2020-06-09 - 2023-02-28 | Financiado
Vacc-iNTS: Advancing a GMMA based vaccine against invasive non typhoidal salmonellosis through Phase 1 trial in... Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan A...
2019-04-30 - 2026-07-31 | Financiado
VacPath: Novel vaccine vectors to resist pathogen challenge Toscana Life Sciences Sviluppo participó en un H2020: H2020-MSCA-ITN-2018 Infectious diseases are a major burden and constant threat to European populations and economies. While barely perceived as a danger not too...
2018-08-30 - 2024-10-31 | Financiado
TRANSVAC2: European Vaccine Research and Development Infrastructure Toscana Life Sciences Sviluppo participó en un H2020: H2020-INFRAIA-2016-2017 TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development...
2017-07-28 - 2023-04-30 | Financiado
VSV-EBOPLUS: SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE Sofia ref. 11606... Toscana Life Sciences Sviluppo tramitó un H2020: H2020-JTI-IMI2-2015-08-single-stage The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycopr...
2017-06-12 - 2023-03-31 | Financiado
IMMUNOSABR: Clinical proof of concept through a randomised phase II study a combination of immunotherapy and st... Toscana Life Sciences Sviluppo participó en un H2020: H2020-SC1-2016-2017 IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-m...
2016-12-12 - 2024-12-31 | Financiado
VSV-EBOVAC: Vaccine safety and immunogenicity signatures of human responses to VSV ZEBOV Sofia ref. 115842 Toscana Life Sciences Sviluppo tramitó un H2020: H2020-JTI-IMI2-2014-02-single-stage The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promis...
2015-03-19 - 2019-02-28 | Financiado
ADITEC: Advanced Immunization Technologies Toscana Life Sciences Sviluppo tramitó un FP7: Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious...
Financiado
IMMOMEC: IMmune MOdulating strategies for treatment of MErkel cell Carcinoma Toscana Life Sciences Sviluppo participó en un FP7: Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered,...
Financiado
PRIAT: Profiling Responders In Antibody Therapies "Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billi...
Financiado
EURENOMICS: European Consortium for High Throughput Research in Rare Kidney Diseases Toscana Life Sciences Sviluppo participó en un FP7: EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and t...
Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... Toscana Life Sciences Sviluppo participó en un FP7: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
Financiado
ATECT: Advanced T cell Engineered for Cancer Therapy Toscana Life Sciences Sviluppo participó en un FP7: "T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize c...
Financiado
IPROVE: Innovation Partnership for a Roadmap on Vaccines in Europe Toscana Life Sciences Sviluppo participó en un FP7: Under the leadership of the major Europe-based vaccine industry players, IPROVE (Innovation Partnership for a Roadmap on Vaccines in Europe)...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.